PMID- 37757826
OWN - NLM
STAT- MEDLINE
DCOM- 20231023
LR  - 20231113
IS  - 2666-3791 (Electronic)
IS  - 2666-3791 (Linking)
VI  - 4
IP  - 10
DP  - 2023 Oct 17
TI  - Clinical development and management of adverse events associated with FGFR 
      inhibitors.
PG  - 101204
LID - S2666-3791(23)00371-3 [pii]
LID - 10.1016/j.xcrm.2023.101204 [doi]
LID - 101204
AB  - Approved fibroblast growth factor receptor (FGFR) inhibitors include erdafitinib, 
      pemigatinib, and futibatinib. We review the most common toxicities associated 
      with FGFR inhibitors and provide practical advice regarding their management. 
      Hyperphosphatemia can be managed with careful monitoring, dose reduction or 
      interruption, a prophylactic low-phosphate diet, and phosphate-lowering therapy. 
      Ocular adverse events (AEs) are managed by withholding or adjusting the dose of 
      the FGFR inhibitor. Dermatologic AEs include alopecia, which can be managed with 
      minoxidil, and dry skin, which can be treated with moisturizers. Hand-foot 
      syndrome can be prevented by lifestyle changes and managed with moisturizing 
      creams, urea, or salicylic acid. Among gastrointestinal AEs, diarrhea may be 
      managed with loperamide; stomatitis can be managed with baking soda rinses, 
      mucosa-coating agents, and topical anesthetics; and dry mouth may be alleviated 
      with salivary stimulants. Most FGFR inhibitor-associated toxicities are 
      manageable with prophylactic measures and treatments; proactive monitoring is key 
      to ensuring optimal clinical benefits.
CI  - Copyright (c) 2023 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Subbiah, Vivek
AU  - Subbiah V
AD  - Sarah Cannon Research Institute, Nashville, TN, USA. Electronic address: 
      vivek.subbiah@scri.com.
FAU - Verstovsek, Srdan
AU  - Verstovsek S
AD  - Department of Leukemia, Division of Cancer Medicine, The University of Texas MD 
      Anderson Cancer Center, Houston, TX, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20230926
PL  - United States
TA  - Cell Rep Med
JT  - Cell reports. Medicine
JID - 101766894
RN  - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 2)
RN  - 0 (Phosphates)
SB  - IM
MH  - *Receptor, Fibroblast Growth Factor, Type 2
MH  - *Phosphates
PMC - PMC10591034
OTO - NOTNLM
OT  - FGFR1
OT  - FGFR2
OT  - FGFR3
OT  - FGFR4
OT  - adverse events
OT  - erdafitinib
OT  - fibroblast growth factor receptor
OT  - futibatinib
OT  - management
OT  - pemigatinib
COIS- Declaration of interests V.S. was affiliated with UT MD Anderson Cancer Center at 
      the time of submission. At the time of submission, V.S. reports a consulting or 
      advisory role with Incyte Corporation; grants from Eli Lilly/Loxo Oncology, 
      Blueprint Medicines Corporation, Turning Point Therapeutics, and Boston 
      Pharmaceuticals; research funding and a consulting or advisory role with Eli 
      Lilly/Loxo Oncology; research funding from Roche/Genentech, Bayer, 
      GlaxoSmithKline, Helsinn Pharmaceuticals, NanoCarrier, Vegenics, Celgene, 
      Northwest Biotherapeutics, Berg Health, Incyte, Fujifilm, D3, Pfizer, MultiVir, 
      Amgen, AbbVie, Alfasigma, Agensys, Boston Biomedical, Idera Pharma, Inhibrx, 
      Exelixis, Blueprint Medicines, Altum Q10, Dragonfly Therapeutics, Takeda, 
      National Comprehensive Cancer Network, NCICTEP, University of Texas MD Anderson 
      Cancer Center, Turning Point Therapeutics, Boston Pharmaceuticals, Novartis, 
      Pharmamar, and MedImmune; an advisory board/consultant position with Helsinn, 
      Incyte Corporation, QED Pharma, Daiichi-Sankyo, Signant Health, Novartis, 
      Janssen, Relay Therapeutics, Roche, and MedImmune; travel funds from Pharmamar, 
      Incyte Corporation, ASCO, and ESMO; and other support from Medscape. S.V. has 
      received honoraria and research support from Incyte Corporation.
EDAT- 2023/09/28 00:42
MHDA- 2023/10/23 01:18
PMCR- 2023/09/26
CRDT- 2023/09/27 18:41
PHST- 2023/03/06 00:00 [received]
PHST- 2023/06/02 00:00 [revised]
PHST- 2023/08/31 00:00 [accepted]
PHST- 2023/10/23 01:18 [medline]
PHST- 2023/09/28 00:42 [pubmed]
PHST- 2023/09/27 18:41 [entrez]
PHST- 2023/09/26 00:00 [pmc-release]
AID - S2666-3791(23)00371-3 [pii]
AID - 101204 [pii]
AID - 10.1016/j.xcrm.2023.101204 [doi]
PST - ppublish
SO  - Cell Rep Med. 2023 Oct 17;4(10):101204. doi: 10.1016/j.xcrm.2023.101204. Epub 
      2023 Sep 26.